Rosolutamide

Rosolutamide

Clinical data
Other names	ASC-JM-17; ASC-JM17; JM17; ALZ-003; ALZ003
Identifiers
IUPAC name (1E,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)hepta-1,6-diene-3,5-dione
CAS Number	1039760-91-2
PubChem CID	25183127
DrugBank	DB16931
ChemSpider	64854816
UNII	5VLL140BN9
ChEMBL	ChEMBL5266600
Chemical and physical data
Formula	C28H32O6
Molar mass	464.558 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC1=C(C=C(C=C1)/C=C/C(=O)C(C(=O)/C=C/C2=CC(=C(C=C2)OC)OC)CC3CCC3)OC
InChI InChI=1S/C28H32O6/c1-31-25-14-10-20(17-27(25)33-3)8-12-23(29)22(16-19-6-5-7-19)24(30)13-9-21-11-15-26(32-2)28(18-21)34-4/h8-15,17-19,22H,5-7,16H2,1-4H3/b12-8+,13-9+ Key:PJOSHEDKRPRCAE-QHKWOANTSA-N

Rosolutamide (INN Tooltip International Nonproprietary Name; developmental code name ASC-JM17, JM17, ALZ-003) is an agonist of nuclear respiratory factor 1 (NRF1), a nonsteroidal antiandrogen, and an androgen receptor degrader related to curcumin. ^{[1] [2] [3] [4] [5]} Other analogues like dimethylcurcumin (ASC-J9) are also known. ^{[2] [6]}

See also

• List of investigational sex-hormonal agents § Androgenics

References

1. "Proposed INN: List 131 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 38 (2): 428. 2024.
2. Chang KH, Chen CM (May 2024). "The Role of NRF2 in Trinucleotide Repeat Expansion Disorders". Antioxidants. 13 (6): 649. doi: 10.3390/antiox13060649 . PMC   11200942 . PMID   38929088.
3. Yuan J, Zhang S, Zhang Y (December 2018). "Nrf1 is paved as a new strategic avenue to prevent and treat cancer, neurodegenerative and other diseases". Toxicology and Applied Pharmacology. 360: 273–283. Bibcode:2018ToxAP.360..273Y. doi:10.1016/j.taap.2018.09.037. PMID   30267745.
4. Bott LC, Badders NM, Chen KL, Harmison GG, Bautista E, Shih CC, et al. (May 2016). "A small-molecule Nrf1 and Nrf2 activator mitigates polyglutamine toxicity in spinal and bulbar muscular atrophy". Human Molecular Genetics. 25 (10): 1979–1989. doi:10.1093/hmg/ddw073. PMC   5062587 . PMID   26962150.
5. Wu YL, Chang JC, Chao YC, Chan H, Hsieh M, Liu CS (July 2022). "In Vitro Efficacy and Molecular Mechanism of Curcumin Analog in Pathological Regulation of Spinocerebellar Ataxia Type 3". Antioxidants. 11 (7): 1389. doi: 10.3390/antiox11071389 . PMC   9311745 . PMID   35883884.
6. Sangotra A, Lieberman AP (February 2025). "Therapeutic targeting of the polyglutamine androgen receptor in Spinal and Bulbar Muscular Atrophy". Expert Opinion on Therapeutic Targets: 1–13. doi:10.1080/14728222.2025.2464173. PMID   39915972.